<div id="readability-page-1"><p>In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Bayer, with a price target of <span id="expert-recommendation-target">€50.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Pitman CFA is a 4-star analyst with an average return of <span>11.4%</span> and a 52.83% success rate.</p> <p>In addition to Barclays, Bayer also received a Buy from UBS’s Matthew Weston in a report issued on May 13. However, on the same day, Deutsche Bank  maintained a Hold rating on Bayer (LSE: 0P6S).</p></div>

BAYRY

SBIO

<p>Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.</p>

Tip Ranks

Bayer

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Barclays

Bayer Aktiengesellschaft

UBS Group AG

Deutsche Bank AG

Bayer AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Barclays Remains a Buy on Bayer (0P6S)